IP Library Granted Patent US 12,431,104
Granted Patent B2
US 12,431,104 · App. 18/611,185 · Granted Sep 30, 2025

Display for pump

Inventors: Michael L. Blomquist (Blaine, MN); Timothy B. Bresina (Shoreview, MN); Gail Beth Bynum (Brooklyn Park, MN); Michael D. Welsch (Stillwater, MN)
Assignee: TANDEM DIABETES CARE, INC.
G09G3/344A61M5/142G09G3/2003G09G3/3466G16H20/17G16H40/63G16H50/30A61M2205/502G09G2330/022G09G2380/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,431,104
App. No.
18/611,185
Granted
Sep 30, 2025
Kind
B2
Abstract

An apparatus comprising a pump configured to deliver insulin, a processor, and a user interface including a color display. Color on the display can be used to bring a user's attention to a change in status of the device or a detected change in status of the patient.

Claims (44)

1. An ambulatory infusion pump system, comprising:

a user interface including a color display configured to display information to a user in a plurality of colors;

a memory configured to store parameters relating to treatment of the user with an ambulatory infusion pump; and

a processor configured to control the information displayed on the color display, the processor further configured to:

receive information relating to a clinical status of the user;

display information relating to the clinical status of the user on a portion of the color display in a first color;

compare the information relating to the clinical status of the user to the parameters relating to treatment of the user upon receiving the information relating to clinical status of the user; and

change the information relating to the clinical status of the user on the portion of the color display from the first color to a second color to indicate a change in the clinical status of the user.

2. The ambulatory infusion pump system of claim 1 , further comprising an ambulatory infusion pump.

3. The ambulatory infusion pump system of claim 2 , wherein the user interface is part of the ambulatory infusion pump.

4. The ambulatory infusion pump system of claim 2 , wherein the user interface is part of a device that is separate from the ambulatory infusion pump.

5. The ambulatory infusion pump system of claim 1 , wherein changing the color of the information relating to the clinical status of the user on the portion of the color display includes altering a color of text on the color display.

6. The ambulatory infusion pump system of claim 1 , wherein changing the color of the information relating to the clinical status of the user on the portion of the color display includes displaying a color flashing indicator.

7. An ambulatory infusion pump system, comprising:

a user interface including a color display configured to display information to a user in a plurality of colors;

a memory configured to store parameters relating to treatment of the user with an ambulatory infusion pump; and

a processor configured to control the information displayed on the color display, the processor further configured to:

receive information relating to a clinical status of the user;

display information relating to the clinical status of the user on a portion of the color display in a first color;

compare the information relating to the clinical status of the user to the parameters relating to treatment of the user upon receiving the information relating to clinical status of the user; and

change the portion of the color display from the first color to a second color to indicate a change in the clinical status of the user,

wherein the change in clinical status of the user relates to an amount of active insulin in the user's body.

8. An ambulatory infusion pump system, comprising:

a user interface including a color display configured to display information to a user in a plurality of colors; and

a processor configured to control the information displayed on the color display, the processor further configured to:

display information relating to a clinical status of the user on a portion of the color display in a first color;

detect a change in the clinical status of the user; and

change the information relating to the clinical status of the user on the portion of the color display from the first color to a second color to indicate the change in the clinical status of the user.

9. The ambulatory infusion pump system of claim 8 , further comprising an ambulatory infusion pump.

10. The ambulatory infusion pump system of claim 9 , wherein the user interface is part of the ambulatory infusion pump.

11. The ambulatory infusion pump system of claim 9 , wherein the user interface is part of a device that is separate from the ambulatory infusion pump.

12. The ambulatory infusion pump system of claim 8 , wherein the change in clinical status of the user relates to an amount of active insulin in the user's body.

13. The ambulatory infusion pump system of claim 8 , wherein changing the color of the information relating to the clinical status of the user on the portion of the color display includes altering a color of text on the color display.

14. The ambulatory infusion pump system of claim 8 , wherein changing the color of the information relating to the clinical status of the user on the portion of the color display includes displaying a color flashing indicator.

15. An ambulatory infusion pump system, comprising:

a color display configured to display information to a user in a plurality of colors; and

a processor configured to control the information displayed on the color display, the processor further configured to:

display text relating to the clinical status of the user on a portion of the color display in a first color;

detect a change in the clinical status of the user; and

change the text relating to the clinical status of the user from the first color to a second color to indicate the change in the clinical status of the user.

16. The ambulatory infusion pump system of claim 15 , further comprising an ambulatory infusion pump.

17. The ambulatory infusion pump system of claim 16 , wherein the color display is part of the ambulatory infusion pump.

18. The ambulatory infusion pump system of claim 16 , wherein the color display is part of a device that is separate from the ambulatory infusion pump.

19. The ambulatory infusion pump system of claim 16 , wherein the change in clinical status of the user relates to an amount of active insulin in the user's body.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 27, 2024
From: SMITHS MEDICAL ASD, INC.
To: TANDEM DIABETES CARE, INC.
Reel/Frame 069087/0717 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 27, 2024
From: BLOOMQUIST, MICHAEL; BRESINA, TIMOTHY; BYNUM, GAIL; WELSCH, MICHAEL
To: SMITHS MEDICAL MD, INC.
Reel/Frame 068721/0966 →
MERGER Recorded Sep 27, 2024
From: SMITHS MEDICAL MD, INC.
To: SMITHS MEDICAL ASD, INC.
Reel/Frame 068722/0043 →
Continuity (7)
Continuation 17976292 · Oct 28, 2022
Continuation 17034264 · Sep 28, 2020
Continuation 16401684 · May 2, 2019
Continuation 15407955 · Jan 17, 2017
Continuation 13242116 · Sep 23, 2011
Division 12114033 · May 2, 2008
Related Publication 20240221693A1 · Jul 4, 2024
References Cited (96)
US 5782805A · Meinzer et al. · 1998 [cited by applicant]
US 5822715A · Worthington et al. · 1998 [cited by applicant]
US 7033338B2 · Vilks et al. · 2006 [cited by applicant]
US 7042643B2 · Miles · 2006 [cited by applicant]
US 9238100B2 · Kruse et al. · 2016 [cited by applicant]
US 9335910B2 · Farnan et al. · 2016 [cited by applicant]
US 9381296B2 · Arrizza · 2016 [cited by examiner]
US 9486171B2 · Saint · 2016 [cited by applicant]
US 9669160B2 · Harris et al. · 2017 [cited by applicant]
US 9715327B2 · Rosinko et al. · 2017 [cited by applicant]
US 9814835B2 · Kruse et al. · 2017 [cited by applicant]
US 9833177B2 · Blomquist · 2017 [cited by applicant]
US 9867937B2 · Saint et al. · 2018 [cited by applicant]
US 9867953B2 · Rosinko · 2018 [cited by applicant]
US 10016561B2 · Saint et al. · 2018 [cited by applicant]
US 10052049B2 · Blomquist et al. · 2018 [cited by applicant]
US 10213547B2 · Rosinko · 2019 [cited by applicant]
US 10357606B2 · Rosinko et al. · 2019 [cited by applicant]
US 10357607B2 · Blomquist et al. · 2019 [cited by applicant]
US 10430043B2 · Rosinko et al. · 2019 [cited by applicant]
US 10434253B2 · DiPerna et al. · 2019 [cited by applicant]
US 10549051B2 · Rosinko · 2020 [cited by applicant]
US 10569016B2 · Rosinko · 2020 [cited by applicant]
US 10653834B2 · Kruse et al. · 2020 [cited by applicant]
US 10864322B2 · Saint et al. · 2020 [cited by applicant]
US 10943687B2 · Blomquist · 2021 [cited by applicant]
US 10994077B2 · Rosinko · 2021 [cited by applicant]
US 11116901B2 · Harris · 2021 [cited by applicant]
US 11135362B2 · DiPerna et al. · 2021 [cited by applicant]
US D938457S · Rosinko et al. · 2021 [cited by applicant]
US 11224693B2 · Ulrich et al. · 2022 [cited by applicant]
US 11285263B2 · DiPerna et al. · 2022 [cited by applicant]
US 11291763B2 · Blomquist et al. · 2022 [cited by applicant]
US 11298053B2 · Blomquist · 2022 [cited by applicant]
US 11302433B2 · Blomquist et al. · 2022 [cited by applicant]
US 11324898B2 · Rosinko · 2022 [cited by applicant]
US 11464908B2 · Michaud et al. · 2022 [cited by applicant]
US 11488549B2 · Blomquist · 2022 [cited by examiner]
US 11576594B2 · Blomquist · 2023 [cited by applicant]
US 11607492B2 · Rosinko et al. · 2023 [cited by applicant]
US 11638781B2 · Rosinko · 2023 [cited by applicant]
US 11676694B2 · Kruse et al. · 2023 [cited by applicant]
US 11694794B2 · Farnan et al. · 2023 [cited by applicant]
US 11967292B2 · Blomquist · 2024 [cited by examiner]
US 20060229557A1 · Fathallah et al. · 2006 [cited by applicant]
US 20070093786A1 · Goldsmith · 2007 [cited by examiner]
US 20080122796A1 · Jobs et al. · 2008 [cited by applicant]
US 20080206799A1 · Blomquist · 2008 [cited by applicant]
US 20080228056A1 · Blomquist et al. · 2008 [cited by applicant]
US 20080312512A1 · Brukalo et al. · 2008 [cited by applicant]
US 20090147026A1 · Buck et al. · 2009 [cited by applicant]
US 20090164239A1 · Hayter · 2009 [cited by examiner]
US 20100107150A1 · Kamada et al. · 2010 [cited by applicant]
US 20110152770A1 · DiPerna et al. · 2011 [cited by applicant]
US 20130283196A1 · Farnan et al. · 2013 [cited by applicant]
US 20130331778A1 · Kruse et al. · 2013 [cited by applicant]
US 20130332874A1 · Rosinko et al. · 2013 [cited by applicant]
US 20140171772A1 · Blomquist · 2014 [cited by applicant]
US 20140273042A1 · Saint · 2014 [cited by applicant]
US 20140276419A1 · Rosinko et al. · 2014 [cited by applicant]
US 20140276556A1 · Saint et al. · 2014 [cited by applicant]
US 20140350371A1 · Blomquist et al. · 2014 [cited by applicant]
US 20140378898A1 · Rosinko · 2014 [cited by applicant]
US 20150073337A1 · Saint et al. · 2015 [cited by applicant]
US 20150120317A1 · Mayou et al. · 2015 [cited by applicant]
US 20160030669A1 · Harris et al. · 2016 [cited by applicant]
US 20160082188A1 · Blomquist et al. · 2016 [cited by applicant]
US 20160121047A1 · Kruse et al. · 2016 [cited by applicant]
US 20160199571A1 · Rosinko et al. · 2016 [cited by applicant]
US 20160271325A1 · Farnan et al. · 2016 [cited by applicant]
US 20170000943A1 · Blomquist et al. · 2017 [cited by applicant]
US 20170043085A1 · Rosinko · 2017 [cited by applicant]
US 20170056590A1 · DiPerna et al. · 2017 [cited by applicant]
US 20170182248A1 · Rosinko · 2017 [cited by applicant]
US 20170300206A1 · Rosinko et al. · 2017 [cited by applicant]
US 20180064873A1 · Kruse et al. · 2018 [cited by applicant]
US 20180092578A1 · Blomquist · 2018 [cited by applicant]
US 20180110921A1 · Saint et al. · 2018 [cited by applicant]
US 20180193573A1 · Rosinko · 2018 [cited by applicant]
US 20180361060A9 · Rosinko · 2018 [cited by applicant]
US 20190321552A1 · DiPerna et al. · 2019 [cited by applicant]
US 20190328967A1 · Blomquist · 2019 [cited by applicant]
US 20190350501A1 · Blomquist et al. · 2019 [cited by applicant]
US 20190365997A1 · Harris · 2019 [cited by applicant]
US 20190388015A1 · Blomquist · 2019 [cited by applicant]
US 20200012401A1 · Rosinko et al. · 2020 [cited by applicant]
US 20200016335A1 · DiPerna et al. · 2020 [cited by applicant]
US 20200101226A1 · Rosinko et al. · 2020 [cited by applicant]
US 20200114076A1 · Ulrich et al. · 2020 [cited by applicant]
US 20200171249A1 · Rosinko · 2020 [cited by applicant]
US 20200179603A1 · Rosinko · 2020 [cited by applicant]
US 20200254174A1 · Kruse et al. · 2020 [cited by applicant]
US 20200261649A1 · Michaud et al. · 2020 [cited by applicant]
US 20200368430A1 · Ulrich et al. · 2020 [cited by applicant]
US 20210001044A1 · Michaud et al. · 2021 [cited by applicant]
US 20210012876A1 · Blomquist · 2021 [cited by applicant]